= Members Only
Pathology for Nonpathologists
Hibret A. Adissu, DVM, PhD, DVSc, DACVP
Dr. Hibret Adissu is currently an Anatomic Pathologist at Covance, in Chantilly, VA within Early Development. Prior to joining Covance, he was an Investigative Pathologist at the National Institutes of Health and an Assistant Professor at the University of Toronto School of Medicine and The Toronto Centre for Phenogenomics. He has more than 10 years experience in Experimental and Comparative pathology with expertise in the Pathology of Mouse Models of Human Diseases, Toxicologic Pathology, and Digital Pathology. He received his DVM from Ethiopia in 1993, MSc in Experimental Medicine from University of Tennessee as a Fulbright Scholar in 2000, PhD in Cancer Biology from Purdue University in 2007, and DVSc in Veterinary Anatomic Pathology from the University of Guelph, Canada in 2007. He is a Diplomate of the American College of Veterinary Pathologists (ACVP). He serves as Associate Editor for the journal Veterinary Pathology; section on Animal Models of Human Disease, and as Editorial board member for Toxicologic Pathology. He is also a member of numerous scientific interest groups and committees within the ACVP and STP. He has over 35 peer reviewed publications in areas of comparative/experimental pathology, animal models of human disease, and cancer biology, and has won awards for teaching and scientific presentations.
Marie Bockenstedt, DVM, PhD, DACVP
Dr. Marie Bockenstedt is an anatomic pathologist currently working in safety assessment at Covance, Inc., in Madison, Wisconsin. Her work at Covance primarily involves acting as a toxicologic study pathologist and providing scientific assistance to the immunohistochemistry and digital imaging teams. Before working at Covance, she completed her DVM, PhD, and pathology residency at Iowa State University College of Veterinary Medicine. Her PhD work focused on antibody-enhanced killing of the intracellular parasite Leishmania amazonensis. She became a Diplomate of the American College of Veterinary Pathologists (ACVP) in 2015 and became a Diplomate of the American Board of Toxicology in 2019.
Michael C. Boyle, DVM, PhD, DACVP, DABT, FIATP
Dr. Michael Boyle is a Pathology Director at Amgen, Inc. in Thousand Oaks. As the toxicologist and/or pathologist for a variety of programs across multiple modalities and therapeutic areas, he has contributed to numerous IND/NDAs. He is also the pathology liaison for all outsourced toxicologic pathology work at Amgen. In the cardiovascular space, Dr. Boyle is the toxicologist and pathologist for multiple late-stage assets being developed for the potential treatment of heart failure or cardiovascular disease. He has authored several cardiovascular publications and is a coauthor on the STP Cardiovascular INHAND nomenclature effort for SEND. Dr. Boyle received his DVM from Michigan State University’s College of Veterinary Medicine in 2006. He completed residency training in Toxicologic and Anatomic Pathology at MPI Research and Michigan State University in 2009 and became ACVP board certified the same year. He received his PhD in 2014 studying the chromatin remodeling enzyme Brg1 in early embryonic development and in doxorubicin cardiotoxicity in the lab of Trevor Archer at the NIEHS, concurrently completing a rodent and comparative pathology and toxicology postdoctoral fellowship at the National Toxicology Program and becoming ABT board certified. Dr. Boyle is also a Fellow of the International Academy of Toxicologic Pathology.
Molly H. Boyle, DVM, MPH, DACVP, FIATP
Dr. Molly Boyle received her DVM from Tufts University School of Veterinary Medicine and her master of public health from Tufts Medical School, both in 2006. Dr. Boyle completed residency training in toxicologic and anatomic pathology at Michigan State University, Pfizer, and MPI Research in 2009 and became ACVP board-certified the same year. She is also a Fellow of the International Academy of Toxicologic Pathology. Dr. Boyle held positions at WIL Research and Integrated Laboratory Systems in Research Triangle Park, North Carolina, before joining Covance as a senior pathologist in 2015. In this current role, she focuses on acute and chronic toxicology studies, including carcinogenesis studies in rats and transgenic mice and inhalation studies in small and large animals. She also serves as an internal peer reviewer, study plan/protocol reviewer, and adviser for clients needing consultation on study design and guidance in regulatory matters. Dr. Boyle has an active presentation and publication record and has served on the editorial board for the journal Veterinary Pathology. She has held or holds leadership and/or membership roles in the IACUC and several STP committees, including the Scientific Regulatory and Policy Committee, Tox Path Forum, Career Development and Outreach Committee, Student Outreach and Engagement Task Force, Membership Committee, and Awards Committee. She is currently an Associate Editor for the journal Toxicologic Pathology.
Brad A. Goupil, MS, DVM, PhD, DACVP
Dr. Brad Goupil is a pathologist working in Drug Discovery and Safety Assessment at Covance. Before joining Covance, he completed his doctorate of veterinary medicine and anatomic pathology residency at the University of Minnesota, and his PhD in biomedical and veterinary medical sciences in the Department of Pathobiological Sciences at Louisiana State University. His PhD work focused on the pathophysiology of chikungunya virus–induced arthritis, utilizing animal models of viral arthritis and osteoarthritis, research in BSL-3 and ABSL-3 laboratories, and training in advanced imaging (microCT). He is board certified in anatomic pathology by the American College of Veterinary Pathologists.
Jack R. Harkema, DVM, PhD, DACVP, ATSF
Dr. Jack Harkema is a University Distinguished Professor of Pathobiology and Diagnostic Investigation and the Albert E. and Lois C. Dehn Endowed Chair in Veterinary Medicine at Michigan State University (MSU). He has been a mentor of undergraduate, graduate, medical, and veterinary students; pathology residents; and postdoctoral fellows for over 30 years in respiratory pathology and toxicology. His research focuses on the elucidation of biological mechanisms underlying airway injury caused by inhaled toxicants. Much of his research has centered on the development of animal models of respiratory, cardiovascular, and metabolic diseases to investigate how preexisting illnesses may affect an individual’s susceptibility to environmental or occupational air pollutants. One of his current research efforts is determining how dietary interventions may be used to prevent or treat toxicant triggers of autoimmune disease. His academic career has been fostered by a network of productive collaborations reflected in over 250 peer-reviewed publications with co-authors from over 20 units at MSU and 100 national/international laboratories. Dr. Harkema has been awarded career achievement awards from the American Thoracic Society, the Society of Toxicology, the American Association for Aerosol Research, and the International Society for Aerosol Medicine. He has also received the Outstanding Alumnus Award from the School of Veterinary Medicine at the University of California, Davis; the Distinguished Faculty Award from the College of Veterinary Medicine at MSU; and the Outstanding Mentorship Award from the Society of Toxicologic Pathology.
Leslie A. Obert, DVM, PhD, DACVP
Dr. Leslie Ann Obert is a scientific director of pathology at GlaxoSmithKline (GSK), where she has been for three years. Her primary duties at GSK involve acting as a toxicologic study pathologist, a scientific consultant for drug development projects, and a member of the Nephrology Safety Panel. She received her DVM from the Ohio State University and her PhD from Colorado State University. She also completed an anatomic pathology residency at Colorado State University and is a Diplomate of the American College of Veterinary Pathologists. Dr. Obert has previously worked as a toxicologic study pathologist at Schering Plough (now Merck) and as an investigative pathologist at Pfizer (Ann Arbor, Michigan). She was a manager of the Investigative Pathology Laboratory at Pfizer (Groton, Connecticut) for over a decade, supporting numerous therapeutic areas, with emphasis on oncology and cardiovascular medicine. She was a member of the Pfizer Kidney Council, the Predictive Safety Testing Consortium Nephrotoxicity Subteam, and the ILSI-HESI Nephrotoxicity Working Group. She is currently a member of the Urinary System subcommittee for the Society of Toxicologic Pathology’s INHAND initiative. She is also on the editorial board for Toxicologic Pathology and is a reviewer for multiple journals.
Daniel J. Patrick, DVM, DACVP, DABT
Dr. Daniel Patrick is a toxicologic pathologist and senior scientific director of pathology at Charles River in Mattawan, Michigan. He received his DVM from Iowa State University in 2001 and anatomic pathology training at Michigan State University in 2004, and is board certified by the American College of Veterinary Pathologists and the American Board of Toxicology. He has authored several textbook chapters, presented at ACT annual meetings and webinars, and is an adjunct professor and coordinator for the toxicologic pathology residency program at Michigan State University. He has helped organize the “Pathology for Nonpathologists” course since 2010 and has recently served as an ACT Councilor and Chair of the Society of Toxicologic Pathology’s Scientific and Regulatory Policy Committee.
Bhanu Pratap Singh, BVSc, MS, DACVP, DABT, FIATP
Dr. Bhanu Singh is currently working as Senior Director, Pathology, at Gilead Sciences. Bhanu is a board certified veterinary anatomic pathologist (DACVP) and toxicologist (DABT) and is also a Fellow of International Academy of Toxicologic Pathology (IATP). He has over ten years of industry experience, most recently as Scientific Director, Pathology at Janssen Pharmaceuticals supporting discovery and nonclinical safety of Oncology and Cardiovascular & Metabolic Diseases programs. Dr. Singh has a strong scientific interest in drug discovery (oncology and cardiovascular metabolism), molecular pathology, liver toxicity, development of animal models of human diseases, and chemical carcinogenesis. He has authored over 20 peer-reviewed publications, five book chapters, and 80+ regulatory and research pathology reports and delivered more than 70 presentations in various scientific meetings. Dr. Singh is actively involved in professional activities for various societies of toxicology and pathology, such as Chair for the STP education course committee, and in the past has served as Associate Editor for Drug and Chemical Toxicology, Chair for the IFSTP-IATP webinar committee, and Chair for Dog INHAND committee. Dr. Singh completed his pathology residency training at the Royal Veterinary College, London (United Kingdom). During his residency training, he did internships and externships at Bern University (Switzerland); the University of California, Davis (United States); the Armed Force Institute of Pathology (Washington, DC); and the National Institute of Environmental Health Sciences (NIEHS). After finishing his residency, he worked at NIEHS/NTP (Research Triangle Park, North Carolina) as a Visiting Fellow in Dr. Dave Malarkey’s laboratory. He received his veterinary training at G. B. Pant University (Pantnagar, India) and a masters at Utrecht University (Netherlands).
Thomas J. Steinbach, DVM, DACVP, DABT
Dr. Thomas Steinbach received his DVM from the College of Veterinary Medicine at the University of Minnesota in 1999. In 2002, he entered residency training for veterinary pathology at the Armed Forces Institute of Pathology and received board certification in 2005. From 2005 to 2012, he served as the chief of pathology for the Naval Medical Research Center and as the director, Division of Pathology, at the Walter Reed Army Institute of Research. In 2006, Dr. Steinbach joined Experimental Pathology Laboratories (EPL) as a part-time consultant pathologist. In 2012, he joined EPL full-time as a senior pathologist, in 2014 became director of the North Carolina laboratory, and in 2017 was named Vice President. His areas of interest include electron microscopy, juvenile toxicology, and nanoparticle pathology.
Lindsay Tomlinson, DVM, DVSc
Dr. Lindsay Tomlinson graduated from the Ontario Veterinary College in Guelph, Ontario, Canada, in 1995 and 1999, for her respective degrees. Dr. Tomlinson researched and defended her thesis on chlamydial disease in sheep in the DVSc program. She spent two years as a visiting instructor at North Carolina State University and obtained board certification with the American College of Veterinary Pathologists (ACVP) in anatomic pathology during that time. Dr. Tomlinson worked as a toxicologic pathologist in the Anatomic and Clinical Pathology Departments and as a project representative for drug safety at Bristol-Myers Squibb (BMS) in New Brunswick, New Jersey, for just under 10 years. She earned board certification with the ACVP in clinical pathology and with the American Board of Toxicology (ABT) in toxicology during her time at BMS. Her current position is global pathology leader for a group of anatomic and clinical pathologists at Pfizer Inc. in Cambridge, Massachusetts. Dr. Tomlinson has had a leadership role in the pathology of discovery and developmental drug safety at Pfizer for almost nine years. She has been the project representative for drug safety on numerous projects. She has also been active in her professional societies and has contributed to several regulatory manuscripts. Highlights have included ACVP Awards and Focused Scientific Sessions Chair, American Society for Veterinary Clinical Pathology Regulatory Affairs Committee Chair and President of the Executive Board, and Society of Toxicologic Pathology Scientific and Regulatory Policy Committee Chair and Council member.